Correlation Between Fulgent Genetics and Quest Diagnostics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Fulgent Genetics and Quest Diagnostics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Fulgent Genetics and Quest Diagnostics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Fulgent Genetics and Quest Diagnostics Incorporated, you can compare the effects of market volatilities on Fulgent Genetics and Quest Diagnostics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Fulgent Genetics with a short position of Quest Diagnostics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Fulgent Genetics and Quest Diagnostics.

Diversification Opportunities for Fulgent Genetics and Quest Diagnostics

-0.52
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Fulgent and Quest is -0.52. Overlapping area represents the amount of risk that can be diversified away by holding Fulgent Genetics and Quest Diagnostics Incorporated in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Quest Diagnostics and Fulgent Genetics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Fulgent Genetics are associated (or correlated) with Quest Diagnostics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Quest Diagnostics has no effect on the direction of Fulgent Genetics i.e., Fulgent Genetics and Quest Diagnostics go up and down completely randomly.

Pair Corralation between Fulgent Genetics and Quest Diagnostics

Given the investment horizon of 90 days Fulgent Genetics is expected to under-perform the Quest Diagnostics. In addition to that, Fulgent Genetics is 2.11 times more volatile than Quest Diagnostics Incorporated. It trades about -0.09 of its total potential returns per unit of risk. Quest Diagnostics Incorporated is currently generating about 0.06 per unit of volatility. If you would invest  15,620  in Quest Diagnostics Incorporated on September 2, 2024 and sell it today you would earn a total of  646.00  from holding Quest Diagnostics Incorporated or generate 4.14% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Fulgent Genetics  vs.  Quest Diagnostics Incorporated

 Performance 
       Timeline  
Fulgent Genetics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Fulgent Genetics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Quest Diagnostics 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Quest Diagnostics Incorporated are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong technical and fundamental indicators, Quest Diagnostics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Fulgent Genetics and Quest Diagnostics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Fulgent Genetics and Quest Diagnostics

The main advantage of trading using opposite Fulgent Genetics and Quest Diagnostics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Fulgent Genetics position performs unexpectedly, Quest Diagnostics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Quest Diagnostics will offset losses from the drop in Quest Diagnostics' long position.
The idea behind Fulgent Genetics and Quest Diagnostics Incorporated pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Complementary Tools

Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance